Altre lingue Senti Biosciences, Inc.

Azioni

SNTI

US81726A1007

Prezzo di chiusura Nasdaq Altri mercati azionari 00:00:00 05/07/2024			Variaz. 5gg	Var. 1 gen.
0,3344 ^USD	+2,89%		-19,90%	-49,33%

01/07	I migliori guadagni di mezzogiorno	MT
17/05	Senti Biosciences, Inc. annuncia cambiamenti esecutivi	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Top Midday Gainers	01/07
Senti Bio Awarded California Institute for Regenerative Medicines (CIRM) Grant for Clinical Development of Logic Gated CAR-NK Cell Therapy	01/07
Senti Biosciences, Inc. Announces Executive Changes	17/05
Senti Bio Announces First Patient Dosed in Phase 1 Clinical Trial of SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	13/05
Senti Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	09/05
Senti Bio Announces First Quarter 2024 Results and Reviews Recent Corporate Highlights	09/05
Senti Biosciences, Inc. Announces Executive Changes	02/05
Senti Biosciences, Inc. Appoints Yvonne Li as Interim Chief Financial Officer, Effective May 4, 2024	02/05
Senti Bio Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia (AML)	30/04
Senti Biosciences, Inc. Announces Publication of SENTI-202 Preclinical Data Demonstrating Potential of Logic-Gated CAR-NK Cell Therapy for the Treatment of Acute Myeloid Leukemia	30/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Chief Financial Officer, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Announces Resignation of Deborah Knobelman as Treasurer and Head of Corporate Development, Effective May 3, 2024	26/04
Senti Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	21/03
Earnings Flash (SNTI) SENTI BIOSCIENCES Reports 2023 Revenue $2.6M	21/03
Senti Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21/03
Senti Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Reviews Recent Highlights	21/03
Senti Bio Announces Strategic Steps to Prioritize Investment in Lead Clinical Program	05/01
Spark Therapeutics, Inc. Announces Workforce Reduction	05/01
Top Premarket Gainers	22/12
Senti Bio Announces FDA Clearance of IND Application for SENTI-202 for the Treatment of Relapsed or Refractory Hematologic Malignancies Including Acute Myeloid Leukemia	22/12

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue Senti Biosciences, Inc.

Azioni

SNTI

US81726A1007

Altre lingue

Filtri